Thus, to specifically verify the prognostic impact of HSP27 in HER2+ BC, we analyzed the survival probability of HER2+ BC patients using a dataset from Kaplan-Meier Plotter (KM plotter; http://kmplot.com/analysis) [36], and found that both relapse-free survival (Figure 1A; n = 251; HR, 1.65; 95% CI, 1–2.71; p = 0.046) and distant metastasis-free survival (Figure 1B; n = 119; HR, 2.42; 95% CI, 1.3–4.53; p = 0.0041) were significantly lower in patients highly expressing HSP27 than other patients. Here, ERBB2 is linked to breast cancer.